Trial Profile
A phase 2 study of first line low dose afatinib in advanced non-small-cell lung cancer patients with mutated epidermal growth factor receptor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2020
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Mar 2019 Status changed from active, no longer recruiting to completed.
- 06 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Feb 2015 New trial record